Possible Involvement of Glutamatergic, Adrenergic and Dopaminergic System in Methylphenidate - induced Motor Activity and Mood-related Alterations in Rats

Kowsar Jahanbakshi1, Sulail Fatima2, Majid Motaghinejad1,3*, Manijeh Motevalian1

ABSTRACT

Background & Objective: Methylphenidate (MPH), as a central nervous system stimulant, is often used to manage hyperactive disorders. The literature is scarce regarding the behavioral consequences of chronic MPH treatment and the role of involved receptors. Thus, in the current study involved receptors in MPH-induced anxiety, depression and motor activity disorders were evaluated.

Materials & Methods: Seventy rats were randomly distributed to seven groups (n = 10, per group); they were treated with normal saline, Domoic acid (DOM) (as AMPA/kainite receptor agonist), Bicuculline (BIC) (as GABAα receptor antagonist), Ketamine (KET) (as NMDA receptor antagonist), Yohimbine (YOH) (as Alpha2-adrenergic receptor antagonist), or Haloperidole (HAL) (as D2 dopamine receptor antagonist), simultaneously with MPH (10 mg/kg). On days 11, 17 and 24, some standard behavior tests including Elevated Plus Maze (EPM), Forced Swim Test (FST) and Open Field Test (OFT) were used to investigate anxiety, depression and motor activity disturbances, respectively.

Results: Our study indicated that pretreatment of rats with KET, HAL and YOH abolished MPH induced - mood and motor activity disturbances.

Conclusion: MPH by interacting with Dopaminergic, NMDA and α2-adrenergic receptors induces anxiety, depression and motor activity disorders.

Keywords: Methylphenidate, Anxiety, Depression and Motor activity

Introduction

Methylphenidate (MPH) as central stimulant agent is often used to treat and manage Hyperactive disorders [1]. Abuse or chronic consumption of MPH can cause mood changes such as cognitive impairments [1, 2]. By blocking some neurotransmitter transporters, MPH inhibits the presynaptic reuptake of dopamine, serotonin and norepinephrine, and allows potent stimulation of their respective receptors at post-synaptic end [3].

MPH is structurally similar to amphetamine, although it has less potent and takes much longer time for its action. Moreover, similar to cocaine, it has addictive properties, and therefore it is easily abused [2, 4-6]. Some undesirable effects of this stimulant can be seen during long term therapy, but still the scientific papers are scarce about consequences of MPH long term use [7]. Behavioral alterations following the chronic use of MPH, include increased mood disturbances along with a significant decline in cognitive functions, inclusive of learning and memory [8]. Numerous studies have reported that long term administration of MPH and other amphetamine-like agents can cause neurodegeneration in some brain regions, such as hippocampus and amygdale, thereby affecting brain development and functions [9, 10].

MPH exerts its properties via norepinephrine and dopamine receptors, but its precise mechanism is not completely understood. Moreover, although some studies have demonstrated that MPH may induce long term changes in adult GABAergic system of prefrontal, but the exact mechanism and also the involvement of other receptors have remained unclear [11]. Glutamate system also appears to be involved in MPH – induced enhanced cognition and psychosis, which are frequently observed at low and high-doses of MPH, respectively [12]. Furthermore, the precise role of various neurotransmitter receptors in mediating behavioral effects of MPH is also unclear. Results based on previous data have illustrated, that D2, GABAα, NMDA, AMPA and Alpha2 receptors...
play critical role in anxiety, depression and motor activity disturbances [12-18].

According to the previous reports, MPH can alter brain amines and their receptor function; it possibly exerts its effects via modulating these receptor systems. Keeping in view MPH – induced motor activity disturbance and mood changes, the current study was designed to explore the potential role of D2, GABA\(_A\), NMDA, AMPA and Alpha\(_2\) receptors in modulating these long term mood and motor activity - related disturbances in rats. The current study gives us insight about the role of neurotransmitter different receptors in mood - related effects induction of MPH.

### Materials and Methods

#### Animals

Seventy adult male rats weighing 180-220 gr and nine weeks aged were acquired from the rodent husbandry of Iran University of Medical Sciences (Tehran, Iran). All animals were transferred to the pharmacology department laboratory. Before starting the experiments, the animals were acclimatized to the new environment for 14 days. The animals were maintained at room temperature (22 ± 2°C), and 12h light and dark cycle. The rats were fed with standard food and tap water. All possible efforts were put in, to minimize the animal suffering during the experiment. All procedures were confirmed and approved by the research committee at the college of medicine, Islamic Azad University, Qom Branches (Research ethical code: IR.IAU.QOM.REC.1399.007). The animal experiments were performed according to the guidelines for the care and use of mammals in neuroscience and behavioral researches (National Research Council, 2003) [19]. The ethical aspects of the study were affirmed by the Institutional Animal Ethical Committee.

#### Drug

MPH (Catalog number:M2892), Domoic Acid (DOM) (Catalog number:D6152) and Bicuculline (BIC) (Catalog number:14340 ) were obtained from Sigma-Aldrich (USA). Ketamine (KET) was purchased as ready to use vial from ROTEXMEDICA pharmaceuticals (Germany). Halperidole (HAL) (Batch number: 1425) and Yohimbine (YOH) (Batch number: 14340 ) were obtained from Iran Daru Pharmaceuticals company (Iran). All mentioned drugs were used as API (Active Pharmaceutical Ingredient), which is the standard form of the drug, to use in the experimental studies.

#### Experimental design

Seventy animals were randomly divided into seven groups (n = 10, per group) as follow:

- Control group which treated by normal saline (0.7 ml/rat, i.p.) for 24 days.
- MPH (10 mg/kg, i.p.) treated group for 24 days.
- DOM (400 μg/kg, i.p.) and MPH (10 mg/kg, i.p.) treated group for 24 days.
- BIC (4 mg/kg, i.p.) and MPH (10 mg/kg, i.p.) treated group for 24 days.
- KET (10 mg/kg, i.p.) and MPH (10 mg/kg, i.p.) treated group for 24 days.
- YOH (10 mg/kg, i.p.) and MPH (10 mg/kg, i.p.) treated group for 24 days.
- HAL (10 mg/kg, i.p.) and MPH (10 mg/kg, i.p.) treated group for 24 days.

In the groups receiving receptor antagonist and MPH, there was a gap period of 45 min between the administrations of both agents. The antagonist was injected first, followed by the administration of MPH.

In the behavioral studies 8-12 animals are commonly employed (slightly more than usually used in experimental studies). This number yields smaller standard deviation and keeps the data normally distributed. The reason for using a higher number of animals in behavioral studies is that animals tend to behave differently and diversely, thereby affecting the overall dimension of the results. Therefore, as commonly used by other studies, we used 10 rates for each group (total: 70). However, it could be more accurate if we had precisely determined the sample size.

It should be noted that all animals received mentioned agents for 24 days. Considering the 3 R principles of human experimentation for animals (replacement, reduction and refinement), we used the same animals for performing three behavioral tests. The experiments were designed in such a manner to induce minimal anxiety in the experimental animals. We performed the tests on days 11, 17 and 24, and each test had a 3-hour rest interval. In the morning, we performed the Open Field Test (OFT) as the first one, followed by a 3-hour rest period. Next, we performed Elevated Plus Maze (EPM) and finally, after 3 hours Forced Swim Test (FST) was performed. In this way, anxiety hardly interfered with the test results. Also as mentioned, the presence of 10 animals in each group prevents the occurrence of heterogeneous data and reduces diversity and large standard deviation.

#### Behavior Tests

**Open Field Test (OFT)**

This behavioral test was performed to assess locomotor activity, anxiety and exploratory behavior in treated animals. Animal behavioral analysis was done based on the previous standard studies, employing OFT protocol [20]; the behavior characteristics including: ambulation distance, frequency of rearing, time spent in center square and frequency of central square entries were also recorded [20].

**Forced Swim Test (FST)**

This test was used to assess depression - like behaviors in rats. Immobility and swimming activity were recorded in FST. Animal behavioral analysis was done based on the previous standard works [21].
Elevated Plus Maze (EPM)

This assay was performed to evaluate the pattern of anxiety experimental animals. It was done according to the previously published literature [22]. The time spent in the open and closed arms was recorded for each rat. Moreover, the number of entries into each type of arm was also recorded. More frequent entry and longer duration of stay in open arm were the indicative of lower levels of stress and anxiety.

Statistical analysis

The data were investigated and analyzed using GraphPad PRISM v.6 software (2016) (Graph Pad Company, San Diego, USA). First, the normality of continuous variables (behavioral parameters) was assessed using Kolmogorov–Smirnov test. All data were indicated as means ± standard error. Since the variables were measured and repeated in different days, the difference between the treatment groups was evaluated using one-way ANOVA repeated measures, followed by a multiple comparison test using Tukey-Kramer test; results were considered to be statistically significant at p< 0.05 level.

Results

OFT results

On days 11, 17 and 24, the animals receiving MPH traversed less ambulatory distance. The rearing behavior decreased in the cited animals in comparison to the control group (P<0.05) (Figure-1A and B). Also, the control group had more frequency of central square entrance; they showed increase in time spent in central region of the OFT, as compared to the MPH alone treated group (P<0.05) (Figure-1C and D). Pretreatment of animals with KET, HAL and YOH improved ambulation distance, time spent in the central square and number of entries to central squares in OFT in all days of test (P<0.05) (Figure-1 A - D).

FST results

As shown in figure 2, the animals in the control group compared to MPH 10 mg/kg treated rats, spent more swimming time in the FST, and less time being immobile on days 17 and 24 (P<0.05) (Figure-2A and B). KET, HAL, and YOH abolished the behavioral disturbances, like reduction the swimming time and increase the immobility time, when were assessed on days 17 and 24 in the MPH addicted animal (P<0.05) (Figure-2 A and B).

EPM results

As indicated in figure-3, MPH treated animals showed reduction in the time spend in open arm and frequency of entries into open arm of EPM on day 11, 17 and 24, comparison to the control animals (P<0.05) (Figure-3A)
and C). Moreover, animals treated with MPH spent more time in closed arm, and entered closed arm in comparison to the animals in control group, when assessed on days 17 and 24 of the experiment (P<0.05) (Figure-3B and D). Treatment of animals with KET and YOH suppressed MPH-induced behavioral disturbances; it attenuated time spent in open arm and number of entries into open arm. Finally, it caused escalation in the time spent in closed arm and increased the number of entries into closed arm, when compared to MPH treated group on day 11, 17 and 24 (P<0.05) (Figure-3A, B, C and D).

**Figure 2.** Effect of DOM, BIC, KET, YOH or HAL on MPH-induced alterations in FST behaviors, such as: Swimming time (A) and immobility time (B). All data are presented as Mean ± SEM (N=8).

* P<0.05 vs. MPH treated group
# P<0.05 vs. KET, HAL, YOH

MPH: methylphenidate, BIC: Bicuculline, DOM: Domoic acid, YOH: Yohimbine, KET: Ketamine, HAL: Haloperidole

**Figure 3.** Effect of DOM, BIC, KET, YOH or HAL on EPM behaviors, such as: time spent in open arm (A), time spent in closed arm (B), count of entrance to open arm (C) and count of entrance to closed arm (D). All data are presented as Mean ± SEM (N=8).

* P<0.05 vs. MPH treated group
# P<0.05 vs. KET, HAL, YOH

MPH: methylphenidate, BIC: Bicuculline, DOM: Domoic acid, YOH: Yohimbine, KET: Ketamine, HAL: Haloperidole

**Discussion**

This study indicated that 24 days’ administration of MPH induces motor activity and mood-related disturbances in rodents. Our data showed that NMDA, alpha adrenergic and dopaminergic receptors appear to mediate MPH-induced behavioral effects. We found that treatment of rats with KET, HAL and YOH can
chronic administration of MPH, via modulating \( D_2 \), NMDA and Alpha-2 receptors can reverse motor activity and mood related behavioral dysfunctions in OFT, when is tested on days 11, 17 and 24 of the study [34].

Thus, it can be suggested that inhibition of receptors such as NMDA, Alpha\(_2\) and \( D_2 \) can abolish the MPH-induced behavioral changes. Many previous studies have shown that high activation of NMDA receptors induces anxiety and depression and also modulates motor activity changes [35]. It was shown that activation of \( D_2 \) and NMDA receptors is involved in antidepressant and anxiolytic properties of some new sedative agents [13, 36]. Several studies have also shown that activation of \( D_2 \) or NMDA receptors is responsible for the neurochemical effects of MPH, but the role of these receptor systems in causing MPH - induced mood related behavioral changes remains unclear [13-15]. Current study demonstrated that treatment of animals with KET, HAL and YOH reversed MPH - induced decrease in swimming time and increase the immobility time in FST, during the days 17 and 24 in the MPH treated animals. It also suggests, that MPH triggers motor activity disturbances and anxiety- like behaviors in FST, via activation NMDA, \( D_2 \) and Alpha-2 receptors.

Our data indicated that HAL, KET and YOH administration reduces MPH-induced depressive - like behaviors. As mentioned above many studies have shown that MPH can promote depression in brain by interacting with \( D_2 \), NMDA and Alpha-2 receptors [12-16]. Previous studies have expressed that various dosage regimen of MPH administration can activate signaling pathway for depression [37, 38]. It was demonstrated that normal physiological activity of \( D_2 \), NMDA and Alpha-2 receptor can stimulate brain functioning against depression [12-18]. These data also demonstrated that increased activation or even increased inhibition of this receptor can induce depression [12-18].

According to the current study, MPH could promote depression – like behaviors in FST, by modulating \( D_2 \), NMDA and Alpha-2 receptors. In addition, blockade of these receptors can suppress MPH - induced depression - like behaviors in FST.

Current study suggested that \( D_2 \), NMDA and Alpha-2 receptors are involved in depressive effect of MPH. Treatment with DOM, KET and YOH led to increase the time spent in open arm and entrance count to open arm, and also decreased time spent in closed arm and count of entrance to closed arm in EPM, on days 11, 17 and 24 in the MPH addicted rats; it has been confirmed by previous studies [12-18]. It was demonstrated that high activation of \( D_2 \), NMDA and Alpha-2 receptors can modulate anxiety pathways, and there are multiple mechanisms for this effect [12-16]. In essence, the current study showed that MPH by activation of \( D_2 \), NMDA and Alpha-2 receptor can cause anxiety; blockade of these receptors can also suppress anxiety associated with MPH abuse. Our results confirmed the
effects of these receptors on behavioral changes of MPH administration.

**Conclusion**

The present study suggested the effects of chronic MPH administration at high doses, on motor activity and mood-related changes. Furthermore, our findings suggested the importance of NMDA, D2 and Alpha-2 receptors in mediating these behavioral malicious effects. The data indicated that long term administration of MPH, via modulating Alpha-2, D2 and NMDA receptors can reverse anxiety and depression-like behaviors and motor activity disturbances, as observed in OFT, EPM (during days 11, 17 and 24) and FST (during days 17 and 24).

**Acknowledgments**

None.

**Conflict of Interest**

None.

**References**


